FDA approves Rigel Pharmaceuticals’ drug for rare bleeding disorder

Share this post

(Reuters) – The U.S. Food and Drug Administration on Tuesday approved Rigel Pharmaceuticals Inc’s treatment for a rare bleeding disorder.

This post was syndicated from Reuters: Health News. Click here to read the full text on the original website.

Share this post

Be the first to comment

Leave a Reply